Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced highlights of data from its Lymphoseek® (technetium Tc 99m tilmanocept) Injection studies in patients with breast cancer, melanoma and head and neck cancer that were presented at the recent Joint International Oncology Congress (JIOC), from May 27-29, 2013. Six studies were presented, featuring new technical insights on the unique binding mechanism of Lymphoseek and comparative performance characteristics of the product in the clinical setting.
Help employers find you! Check out all the jobs and post your resume.
